Genentech presents Actemra ROSE trial data
Additionally, combined data from three other Phase III studies showed that RA patients who received Actemra had sustained improvements in signs and symptoms over nearly two years. Across
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Lodotra is a proprietary programmed-release formulation of low-dose prednisone and has received regulatory approval in Europe for reduction in morning stiffness associated with rheumatoid arthritis (RA). Merck Serono